<DOC>
	<DOCNO>NCT02023996</DOCNO>
	<brief_summary>This study divide two group . The purpose first group ( Group 1 ) find optimal time take picture injection 89Zr-DFO-trastuzumab , see long stayed blood , see well tolerate . From investigator learn Group 1 , patient Group 2 long need serial scan serial blood draw . For Group 2 , patient receive injection 89Zr-DFO-trastuzumab monitor follow injection . The patient ask return picture 5-8 day injection determine well study drug attache tumor well tolerate</brief_summary>
	<brief_title>PET Imaging With 89Zr-DFO-Trastuzumab Esophagogastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Registered patient MSKCC Age ≥18 year Pathologically cytologically confirm metastatic primary esophagogastric cancer HER2 positive status FISH IHC currently implement patient esophagogastric cancer . HER2 overexpression and/or amplification determine immunohistochemistry ( 3+ ) FISH ( ≥2.0 ) Measurable evaluable disease , lesions previously radiate , clinically indicate image evaluation perform within 4 week prior study entry ( CT , MRI , FDG PET bone scan ) . Patients require concurrent radiation treatment eligible unless additional lesion irradiate assessable target present . Karnofsky Performance Score ≥ 60 Ability understand willingness sign inform consent Negative pregnancy test , perform female patient childbearing potential within 1week administration radioactive material . Life expectancy least three ( 3 ) month . Willingness use birth control study . The patient ask consent provide access data obtain molecular analysis do archived tumor tissue correlate 89ZrDFOtrastuzumab imaging result . Concurrent therapy allow . Inability lie still duration scan procedure . Patients know sensitivity contraindication component 89ZrDFOtrastuzumab ( 89Zr Desferroxamine ( DFO ) trastuzumab ) Patients receive trastuzumab must least washout period trastuzumab 14 day , apply 89ZrDFOtrastuzumab repeat , post treatment assessment patient may receive trastuzumab . HIV positive active hepatitis . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification 3 , unstable angina poorly control arrhythmia . Myocardial infarction within 6 month prior study entry Hematologic Platelets &lt; 50K/mcL ANC &lt; 1.0 K/mcL Hepatic laboratory value Bilirubin &gt; 2 x ULN ( institutional upper limit normal ) , exception patient Gilberts disease . AST/ALT &gt; 2.5 x ULN ( institutional upper limit normal ) ; &gt; 5 x ULN liver metastasis Renal laboratory value Estimated GFR ( eGFR ) &lt; 30mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2 positive</keyword>
	<keyword>PET Imaging</keyword>
	<keyword>89Zr-DFO-trastuzumab</keyword>
	<keyword>13-165</keyword>
</DOC>